Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era
Abstract Since 2004, multiple blockbuster drugs have been approved for men with metastatic prostate cancer. Nevertheless, it has been reported that no improvement in survival was observed between 2004 and 2009. Herein, we have analyzed the SEER database to assess the survival outcome of metastatic p...
Guardado en:
Autores principales: | Isaac E. Kim, Thomas L. Jang, Sinae Kim, David Y. Lee, Daniel D. Kim, Eric A. Singer, Saum Ghodoussipour, Mark N. Stein, Monish Aron, Marc A. Dall’Era, Isaac Yi Kim |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f0308822a4d1411cbcaa1149414a27a7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
por: Nikolai A. Ognerubov
Publicado: (2021) -
Advanced Therapeutic Options for Treatment of Metastatic Castration Resistant Prostatic Adenocarcinoma
por: Faiza Naseer, et al.
Publicado: (2021) -
An exploratory first‐in‐man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2‐ and 1‐week interval in patients with metastatic castration resistant prostate cancer
por: Josephina P. M. Vrouwe, et al.
Publicado: (2021) -
Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients
por: Benedikt Hoeh, et al.
Publicado: (2021) -
Increase in Apoptosis and of the Stress Protein HSP70 in the Mouse Epididymis Produced by the Antiandrogen Flutamide
por: Bustos Obregón,Eduardo, et al.
Publicado: (2009)